Table 2.
Uni- and multivariate Cox proportional-hazard analyses for disease progression in HCC patients
| Disease progression criteria | Univariate analysis | Multivariate analysis | Schoenfeld residuals | ||
|---|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | p-value | |
| aLength of the specific PFI | |||||
| Age | 0.99 (0.98–1.00) | 0.15 | – | – | – |
| Gender (m/f) | 0.87 (0.58–1.29) | 0.48 | – | – | – |
| Tumor grade (G1 vs. G2) | 0.54 (0.30–0.97) | 0.04* | 0.54 (0.28–1.07) | 0.08(*) | 0.14 |
| Tumor grade (G3/G4 vs. G2) | 1.14 (0.73–1.80) | 0.56 | 1.25 (0.78–2.02) | 0.35 | |
| Tumor stage (stage II vs. stage I) | 1.78 (1.06–3.00) | 0.03* | 1.73 (1.01–2.93) | 0.04* | 0.02 |
| Tumor stage (stage III/IV vs. stage I) | 1.96 (1.19–3.24) | 0.01* | 2.12 (1.26–3.55) | < 0.01* | |
| IFNL3 rs4803217 genotype (CA/AA vs. CC) | 1.10 (0.74–1.63) | 0.65 | – | – | – |
| aOS time | |||||
| Age | 1.03 (1.01–1.05) | 0.02* | 1.02 (1.00–1.04) | 0.02* | 0.93 |
| Gender (m/f) | 1.10 (0.70–1.73) | 0.67 | – | – | – |
| Tumor grade (G1 vs. G2) | 0.50 (0.25–1.00) | 0.05* | 0.53 (0.27–1.07) | 0.08(*) | 0.25 |
| Tumor grade (G3/G4 vs. G2) | 0.91 (0.53–1.55) | 0.72 | 1.01 (0.58–1.75) | 0.96 | |
| Tumor stage (stage II vs. stage I) | 0.94 (0.50–1.79) | 0.85 | – | – |
- - |
| Tumor stage (stage III/IV vs. stage I) | 1.31 (0.75–2.26) | 0.34 | – | – | |
| IFNL3 rs4803217 genotype (CA/AA vs. CC) | 1.11 (0.71–0.74) | 0.66 | – | – | – |
a Cox regression analyses were performed for complete data sets (n = 167)
* significant p-value (p ≤ 0.5)
(*) tendency to significant p-value (p ≤ 0.1)
Results with a 95% CI including 1 and/or a significant Schoenfeld residual have to be considered with reservation.